scientific programme - emuc19 vienna 8th meeting of the ...s. shariat, vienna (at) 11:15 - 11:25...

8th Meeting of the EAU Section of Urological ImagingESUI Meeting

Thursday 14November08:30 - 18:00

Location Hall G1

Scientific Programme - EMUC19 Vienna

2

Oligometastases in genito urinary cancersESU Course 01


Location Hall K1

Chair T. Maurer, Hamburg (DE)

09:00 - 09:05 European School of Urology: A unique possibility for urological educationP.J. Van Leeuwen, Badhoevedorp (NL)

09:05 - 09:10 Introduction and aims

09:10 - 09:40 Definitions and biology of oligometastasesP.J. Van Leeuwen, Badhoevedorp (NL)

09:40 - 10:10 Role of imaging modalitiesT. Maurer, Hamburg (DE)

10:10 - 10:30 Break

10:30 - 11:00 Radiotherapeutic management of oligometastases in prostate cancerG. De Meerleer, Leuven (BE)

11:00 - 11:30 Salvage surgical treatment of nodal metastasesT. Maurer, Hamburg (DE)

11:30 - 11:55 Role of systemic therapy in oligometastasized diseaseP.J. Van Leeuwen, Badhoevedorp (NL)

11:55 - 12:00 Take home messages and close


3

YAU Autumn MeetingYAU Meeting


Location Hall G2

Moderator M.S. Silay, Istanbul (TR)

Discussant To be confirmed

10:00 - 10:10 YAU OverviewM.S. Silay, Istanbul (TR)

10:10 - 11:00 YAU Working parties reports

10:10 - 10:15 Renal Cell CarcinomaU. Capitanio, Milan (IT)

10:15 - 10:20 Prostate CancerG. Gandaglia, Milan (IT)

10:20 - 10:25 UrothelialE. Xylinas, Paris (FR)

10:25 - 10:30 Endourology & UrolithiasisP. Kallidonis, Patras (GR)

10:30 - 10:35 Pediatric UrologyB. Haid, Linz (AT)

10:35 - 10:40 Men’s HealthG.I. Russo, Catania (IT)

10:40 - 10:45 Functional UrologyT.A.T. Marcelissen, Maastricht (NL)

10:45 - 10:50 ERUS-RoboticG. De Naeyer, Aalst (BE)

10:50 - 10:55 UrotechnologyD. Veneziano, Reggio Calabria (IT)

10:55 - 11:00 ReconstructiveL.A. Kluth, Frankfurt a.M. (DE)

11:00 - 11:15 Establishing a professional career at a European level: Motivational talk by aCrystal Matula Award WinnerS. Shariat, Vienna (AT)

11:15 - 11:25 Young Urologist Leadership CourseH. Rijksen, Maarsbergen (NL)


4

YAU Round TablesYAU Round tables


Location Hall K2


5

PRIAS meetingPRIAS


Location Hall F2

13:00 - 13:10 Welcome and IntroductionC.H. Bangma, Rotterdam (NL)M.J. Roobol, Rotterdam (NL)

13:10 - 13:30 Overview of PRIAS , status 2019H.B. Luiting, Rotterdam (NL)

13:30 - 13:45 PRIAS JapanM. Sugimoto, Kagawa (JP)

13:45 - 14:00 Diet /interventions in men on ASL.D.F. Venderbos, Rotterdam (NL)

14:00 - 14:20 Quality of Life in ASL. Bellardita, Milano (IT)

14:20 - 14:40 Coffee break

14:40 - 15:00 The role of genetics in ASG. Jenster, Rotterdam (NL)

15:00 - 15:15 PRIAS and the GDPRL.D.F. Venderbos, Rotterdam (NL)J. Helleman, Rotterdam (NL)

15:15 - 15:35 The new PRIAS websiteH.B. Luiting, Rotterdam (NL)

15:35 - 15:50 PIONEER and PRIASM.J. Roobol, Rotterdam (NL)

15:50 - 16:10 Coffee break

16:10 - 16:25 Movember GAP-3: joining forces 2.0J. Helleman, Rotterdam (NL)

16:25 - 17:00 Different aspects of MRI in Active Surveillance; What can PRIAS and GAP-3contribute?C. Moore, London (GB)F. Giganti, London (GB)

17:00 - 18:00 Future of PRIAS, sustainability, new projectsA. Rannikko, Helsinki (FI)

18:00 - 18:15 Summary, the way forward, announcement of award winnersC.H. Bangma, Rotterdam (NL)M.J. Roobol, Rotterdam (NL)


6

Current applications and future perspectives of liquid biopsies in Uro-OncologyEAU Section Uro-Pathology (ESUP) Symposium, organized with EAU Section Urological Research (ESUR) andEuropean Society of Pathology Uropathology Working Group


Location Hall G2

Chairs R. Montironi, Ancona (IT)A. Lopez-Beltran, Lisbon (PT)K. Junker, Homburg (DE)H.P.A.M. Van Poppel, Leuven (BE)

13:30 - 13:35 IntroductionH.P.A.M. Van Poppel, Leuven (BE)

13:35 - 14:00 Current applications of liquid biopsies: What we need to know before startingusing them?M. Fiorentino, Bologna (IT)

14:00 - 14:25 Molecular characterization and diagnostic criteria of kidney cancer with emphasison liquid biopsiesK. Junker, Homburg (DE)

14:25 - 14:50 An evaluation of current prostate cancer diagnostic approaches with emphasis onliquid biopsiesM. Eckstein, Erlangen (DE)

14:50 - 15:15 Liquid biopsies and bladder cancerT. Gevaert, Leuven (BE)

15:15 - 15:40 Current bladder cancer biomarkers with emphasis on urine biomarkersA. Lopez-Beltran, Lisbon (PT)

15:40 - 16:05 Future perspectives of liquid biopsies in Uro-OncologyS. Riethdorf, Hamburg (DE)

16:05 - 16:30 Discussion and conclusionsR. Montironi, Ancona (IT)


7

Immunotherapy for urological tumoursESU Course 02


Location Hall K1

Chair R.J.A. Van Moorselaar, Amsterdam (NL)

14:00 - 14:05 European School of Urology: A unique possibility for urological educationR.J.A. Van Moorselaar, Amsterdam (NL)

14:05 - 14:25 Update and current knowledge of immunotherapy in prostate cancerR.J.A. Van Moorselaar, Amsterdam (NL)

14:25 - 14:55 Immunotherapy for urological tumours: Clinical cases in prostate cancerR.J.A. Van Moorselaar, Amsterdam (NL)

14:55 - 15:15 Break

15:15 - 15:35 Update and current knowledge of immunotherapy in renal cancerM-O. Grimm, Jena (DE)

15:35 - 16:05 Immunotherapy for urological tumours: Clinical cases in renal cancerM-O. Grimm, Jena (DE)

16:05 - 16:25 Update and current knowledge of immunotherapy in bladder cancerR.J. Jones, Glasgow (GB)

16:25 - 16:55 Immunotherapy for urological tumours: Clinical cases in bladder cancerR.J. Jones, Glasgow (GB)

16:55 - 17:00 Closing remarks


8

Morphologic and molecular classification of bladder cancerUropathology Course


Location Hall G2

Chairs R. Montironi, Ancona (IT)A. Lopez-Beltran, Lisbon (PT)D. Ertoy Baydar, Istanbul (TR)

Learning objectivesThe joint histological evaluation of specimens of bladder and prostate cancer by theclinician and uropathologist can produce much more clinical and prognosticinformation than that contained in the final histopathology report. Both the clinicianand uropathologist can benefit from such an approach. The former will more clearlyunderstand and explain the preoperative features of the cancer, the intraoperativefindings, and postoperative follow-up of the patient. The experience acquired wouldhelp improve him/her diagnostic and prognostication capabilities and surgical skill.The uropathologist will learn the great clinical significance of his/her daily routine. Thecourse will be based on the projection and discussion of virtual slides.


9

ESU barcode 2ESU 2 barcodes


Location Hall K1


10

Welcome and introduction

Friday 15 November08:30 - 08:40

Location Auditorium

Chairs L. Albiges, Villejuif (FR)P. Hoskin, Northwood (GB)H.P.A.M. Van Poppel, Leuven (BE)


11

Early detection of prostate cancer 40 years later. The 40th birthday of PSA


Location Auditorium

Chairs T. Wiegel, Ulm (DE)R. Oyen, Leuven (BE)E. Compérat, Paris (FR)C.H. Bangma, Rotterdam (NL)

08:40 - 08:45 PSA screening has to come backH.P.A.M. Van Poppel, Leuven (BE)

08:45 - 08:55 The story of PSAM.J. Roobol, Rotterdam (NL)

08:55 - 09:05 Early detection in prostate cancer in 2019P. Albers, Düsseldorf (DE)

09:05 - 09:15 Prostate cancer screening by MRI: Will it ever happen?H. Thoeny, Bern (CH)

09:15 - 09:25 Prostate cancer morphology: Major changes with clinical significance in the last40 yearsR. Montironi, Ancona (IT)

09:25 - 09:40 Discussion

09:40 - 09:50 Biomarkers for early detection: Real game changers?G. Jenster, Rotterdam (NL)

09:50 - 10:00 Medical application of prostate cancer genomicsM.A. Rubin, Berne (CH)



12

Course 1 - ESU/ESUI Hands-on Training Course in Prostate MRI reading forurologistHOT MRI reading


Location Room 0.94 - 0.95

Chair J. Walz, Marseille (FR)

Tutors F. Sanguedolce, Barcelona (ES)J.J. Futterer, Nijmegen (NL)G. Giannarini, Udine (IT)V. Panebianco, Rome (IT)


13

Course 1 -ESU/ESUI Hands-on Training Course in MRI Fusion biopsyHOT MRI Fusion 1



Chair L. Budäus, Hamburg (DE)

Tutors J.P. Radtke, Essen (DE)E. Baco, Oslo (NO)S. Boxler, Bern (CH)A. Borkowetz, Dresden (DE)A. Maxeiner, Berlin (DE)


14

Coffee break and poster viewing


Location Foyer


15

Prostate cancer: From active surveillance to active treatmentMultidisciplinary case discussion


Location Auditorium

Chairs B. De Bari, Besancon (FR)G.N. Thalmann, Bern (CH)

11:00 - 12:00 Multidisciplinary case discussion From active surveillance to active treatmentCase presenter G. Ploussard, Toulouse (FR)Discussants F. Montorsi, Milan (IT)

T. Gevaert, Kluisbergen (BE)A. Bossi, Villejuif (FR)R. Renard-Penna, Paris (FR)L.H. Klotz, Toronto (CA)


16

Highlights in GU cancersPlenary Session 03


Location Auditorium

Chairs J. Walz, Marseille (FR)R. Oyen, Leuven (BE)

12:00 - 12:10 Results of the APCCC meetingN. Mottet, Saint-Étienne (FR)

12:10 - 12:20 Highlights from ESUIG. Salomon, Hamburg (DE)

12:20 - 12:30 The EAU Research Foundation: Trials in progressA.S. Bjartell, Malmö (SE)

12:30 - 12:40 Highlights from PRIASM.J. Roobol, Rotterdam (NL)


17

Lunch break and poster viewing


Location Foyer


18

Novelties in non-muscle invasive bladder cancer


Location Auditorium

Chairs A. Necchi, Milan (IT)M. Rouprêt, Paris (FR)G. Mikuz, Innsbruck (AT)

14:00 - 14:15 VI-RADS for the management of non-muscle-invasive bladder cancerV. Panebianco, Rome (IT)

14:15 - 14:30 Intravesical alternatives for non-muscle-invasive bladder cancer treatmentA.M. Kamat, Houston (US)

14:30 - 14:40 Novel biomarkers - urinary markers for in non-muscle-invasive bladder cancerL. Dyrskjøt, Aarhus (DK)

14:40 - 14:55 Morphological changes after therapyA. Lopez-Beltran, Lisbon (PT)



19

Course 2 - ESU/ESUI Hands-on Training Course in MRI Fusion biopsyHOT MRI Fusion 2



Chair L. Budäus, Hamburg (DE)

Tutors K. Gunzel, Berlin (DE)To be confirmedTo be confirmedTo be confirmed

14:00 - 16:00 Introduction to HitachiA. Maxeiner, Berlin (DE)


20

Nightmare session: It could happen to you…


Location Auditorium

Chairs C. Cozzarini, Milan (IT)A. Stenzl, Tübingen (DE)

15:15 - 15:25 SurgeryR. Sanchez-Salas, Paris (FR)


15:30 - 15:40 Radiation therapyT. Wiegel, Ulm (DE)



21



Location Foyer


22

Challenge the expert


Location Auditorium

Discussants M. De Santis, Berlin (DE)S. Shariat, Vienna (AT)V. Fonteyne, Ghent (BE)R. Renard-Penna, Paris (FR)M. Fiorentino, Bologna (IT)

16:15 - 16:40 Multidisciplinary case discussion Complete response after neoadjuvantchemotherapy or immunotherapyY. Loriot, Villejuif (FR)

16:40 - 17:05 Multidisciplinary case discussion Histological variants in non-muscle invasivebladder cancerM. Moschini, Luzern (CH)

17:05 - 17:30 Multidisciplinary case discussion Upper tract recurrence after cystectomyB.M. Kiss, Bern (CH)


23

New trials updatePlenary Session 07

Saturday 16November08:00 - 09:45

Location Auditorium

Chairs C. Salembier, Brussels (BE)A. Bamias, Athens (GR)T. Maurer, Hamburg (DE)

08:00 - 08:15 The SPCG4 studySpeaker P. Stattin, Uppsala (SE)Discussant L.H. Klotz, Toronto (CA)

08:15 - 08:30 The ARAMIS trialSpeaker K. Fizazi, Villejuif (FR)Discussant M. De Santis, Berlin (DE)

08:30 - 08:45 KEYNOTE 057Speaker A.V. Balar, ()Discussant A.M. Kamat, Houston (US)

08:45 - 09:00 Metastatic RCC: First line treatmentSpeaker M. Schmidinger, Vienna (AT)Discussant M-O. Grimm, Jena (DE)

09:00 - 09:15 Duration of androgen deprivation therapy in high-risk prostate cancer: Arandomized phase III trialSpeaker A-G. Martin, ()Discussant P. Hoskin, Northwood (GB)



24

Announcement 3 best unmoderated postersPlenary Session 08


Location Auditorium

Chairs L. Albiges, Villejuif (FR)V. Fonteyne, Ghent (BE)S. Shariat, Vienna (AT)


25



Location Foyer


26

Residual disease after chemotherapy in testicular cancerMultidisciplinary case discussion


Location Auditorium

Case presenter C. Oing, Hamburg (DE)

Discussants A. Heidenreich, Cologne (DE)J. Oldenburg, Lørenskog (NO)F. Giammarile, ()G. De Meerleer, Leuven (BE)L. Rocher, Paris (FR)


27

Late breaking news sessionPlenary Session 10


Location Auditorium

Chairs L. Albiges, Villejuif (FR)E. Xylinas, Paris (FR)

11:00 - 11:11 Update of the IGCCCG classificationS. Gillessen Sommer, Manchester (GB)

P162 Timing of radiotherapy (RT) after radical prostatectomy (RP): First results fromRADICALS RT randomised controlled trial [NCT00541047]By: Parker C. 1 , Clarke N.W. 2 , Cook A. 3 , Kynaston H. 4 , Petersen P.M. 5 , Cross W.6 , Persad R. 7 , Catton C. 8 , Logue J. 9 , Payne H. 10 , Saad F. 11 , Brasso K. 5 ,Lindberg H. 12 , Zarkar A. 13 , Raman R. 14 , Roder M.A. 5 , Heath C. 15 , Parulekar W.16 , Parmar M. 3 , Sydes M. 3

Institutes: 1Royal Marsden NHS Foundation Trust, Dept. of Oncology, Sutton, UnitedKingdom, 2The Christie and Salford Royal Hospitals, Department of Surgery,Manchester, United Kingdom, 3MRC Clinical Trials Unit at UCL, Dept. of Clinical Trials,London, United Kingdom, 4Cardiff School of Medicine, Division of Cancer and Genetics,Cardiff, United Kingdom, 5Rigshospitalet, University Hospital Copenhagen, Dept. ofOncology, Copenhagen, Denmark, 6St James University Hospital, Dept. of Urology,Leeds, Denmark, 7Bristol Urological Institute, North Bristol Hospitals, Dept. of Urology,Bristol, United Kingdom, 8Princess Margaret Hospital/University Health Network, Dept. ofRadiation Oncology, Toronto, Canada, 9The Christie Hospital, Dept. of Oncology,Manchester, United Kingdom, 10University College London Hospitals, Dept. of Oncology,London, United Kingdom, 11Hospital St. Luc du CHUM, Dept. of Urology, Montreal,Canada, 12Herlev Hospital, Dept. of Oncology, Herlev, Denmark, 13University HospitalBirmingham, Dept. of Oncology, Birmingham, United Kingdom, 14Kent Oncology Centre,Dept. of Clinical Oncology, Canterbury, United Kingdom, 15University HospitalSouthampton, Dept. of Clinical Oncology, Southampton, United Kingdom, 16Queen'sUniversity, Canadian Cancer Trials Group, Dept. of Oncology, Ontario, Canada

P163 Intraprostatic injection of Liproca® Depot (2-hydroxy flutamide) in patient withlocalised prostate cancerBy: Klotz L.H. 1 , Axén N. 2 , Grudén S. 3 , Gauffin C. 4 , Giddens J. 5 , Incze P. 6 , JanszK. 7 , Jievaltas M. 8 , Rendon R. 9 , Ulys A. 10 , Bjartell A. 11 , Tammela T. 12

Institutes: 1University of Toronto, Dept. of Urology, Toronto, Canada, 2LIDDS AB, Dept.of Biomaterials and Devices, Uppsala, Sweden, 3LIDDS AB, Dept. of PharmaceuticalR&D, Uppsala, Sweden, 4LIDDS AB, Dept. of Clinical Development, Uppsala, Sweden,5Jonathan Giddens Medicine Professional Corp, Dept. of Urology, Brampton, Canada,6Oakville Trafalgar Memorial Hospital, Dept. of Urological Surgery, Oakville, Canada,7Burlington Professional Centre, Dept. of Urology, Burlington, Canada, 8Hospital ofLithuanian University of Health Sciences Kauno Klinikos, Dept. of Urology, Kaunas,Lithuania, 9Centre of Applied Urology Research, Dept. of Urology, Halifax, Canada,10National Cancer Institute, Dept. of Oncology, Vilnius, Lithuania, 11Skåne UniversityHospital, Dept. of Translational Medicine, Malmö, Sweden, 12Tampere UniversityHospital, Dept. of Surgery, Tampere, Finland


28

False positives findings in uro-oncology and their clinical impactPlenary Session 11


Location Auditorium

Chairs I.J. De Jong, Groningen (NL)H. Thoeny, Bern (CH)A. Bossi, Villejuif (FR)

11:25 - 11:35 Imaging: PSMA PETD. Deandreis, ()

11:35 - 11:45 Imaging: MRI of the prostateR. Renard-Penna, Paris (FR)

11:45 - 11:55 False positive results in pathologyF. Algaba, Barcelona (ES)



29

Oral presentation of the 6 best abstractsPlenary Session 12


Location Auditorium

Chairs A. Bamias, Athens (GR)C. Salembier, Brussels (BE)A. Briganti, Milan (IT)

O2 Proteome-based classification of non-muscle invasive bladder cancerBy: Fragkoulis C. 1 , Stroggilos R. 2 , Latosinska A. 3 , Makridakis M. 2 , Lygirou V. 2 ,Mavrogeorgis E. 4 , Drekolias D. 5 , Frantzi M. 3 , Mullen W. 6 , Stasinopoulos K. 1 ,Papadopoulos G. 1 , Stathouros G. 1 , Lazaris A. 5 , Makrythanasis P. 2 , Ntoumas K. 1 ,Mischak H. 3 , Zoidakis J. 2 , Vlahou A. 2

Institutes: 1General Hospital of Athens, Dept. of Urology, Athens, Greece, 2BiomedicalResearch Foundation of the Academy of Athens, Dept. of Biotechnology, Athens,Greece, 3Mosaiques Diagnostics GmbH, Mosaiques Diagnostics, Hannover, Germany,4Agricultural University of Athens, Dept. of Biotechnology, Athens, Greece, 5MedicalSchool of Athens, Dept. of Pathology, Athens, Greece, 6British Heart FoundationGlasgow Cardiovascular Research Centre, University of Glasgow, , CardiovascularResearch Centre, Glaskow, United Kingdom

O3 The Phoenix criteria for biochemically recurrent prostate cancer after curativeradiotherapy appear obsolete in the era of prostate-specific membrane antigenPET – a plea for urgent re-evaluation of current guidelinesBy: Jansen B.H.E. 1 , Van Leeuwen P. 2 , Wondergem M. 3 , Van Der Sluis T. 1 ,Nieuwenhuijzen J. 1 , Knol R. 3 , Van Moorselaar J. 1 , Van Der Poel H. 2 , Oprea-LagerD. 4 , Vis A. 1

Institutes: 1Vrije Universiteit, Dept. of Urology, Amsterdam, The Netherlands, 2CancerInstitute, Dept. of Urology, Amsterdam, The Netherlands, 3Noordwest Groep, Dept. ofNuclear Medicine, Alkmaar, The Netherlands, 4Vrije Universiteit, Dept. of Radiology andNuclear Medicine, Amsterdam, The Netherlands

O4 Micro-ultrasound versus multiparametric MRI in the detection of prostate cancer:Results from a prospective single center trialBy: Maffei D. 1 , Paciotti M. 1 , Lazzeri M. 1 , Frego N. 1 , Fasulo V. 1 , Diana P. 1 , RegisF. 1 , Elefante G.M. 2 , Colombo P. 2 , Saita A.R. 1 , Hurle R. 1 , Casale P. 1 , Buffi N.M. 3

, Guazzoni G.F. 3 , Lughezzani G. 3

Institutes: 1Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy,2Humanitas Clinical and Research Center, Dept. of Anatomopathology, Rozzano, Italy,3Humanitas University, Dept. of Urology, Rozzano, Italy

O5 Safety of abiraterone and enzalutamide in prostate cancer patients treated withanticoagulantsBy: Goena Vives M.C. 1 , Rilo I. 2 , Garcia R. 1 , Mañas L. 1 , Beramendi J.R. 2 , QuintasL. 1

Institutes: 1Mendaro Hospital, Dept. of Cardiology, Mendaro, Spain, 2DonostiaUniversity Hospital, Dept. of Cardiology, San Sebastian, Spain


30

O6 Patient-reported outcomes (PROs) From TITAN: A phase 3, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgendeprivation therapy (ADT) in patients (pts) with metastatic castration-sensitiveprostate cancer (mCSPC)By: Agarwal N. 1 , Mcquarrie K. 2 , Bjartell A. 3 , Chowdhury S. 4 , Pereira De SantanaGomes A.J. 5 , Chung B.H. 6 , Özgüroğlu M. 7 , Juárez Soto Á. 8 , Merseburger A.S. 9 ,Uemura H. 10 , Ye D-W. 11 , Given R. 12 , Miladinovic B. 13 , Dearden L. 14 , Deprince K.15 , Naini V. 16 , Lopez-Gitlitz A. 17 , Chi K.N. 18

Institutes: 1University of Utah, Huntsman Cancer Institute, Salt Lake City, United Statesof America, 2Janssen Research & Development, Strategic Market Access, Horsham,United States of America, 3Skåne University Hospital, Lund University, Malmo, Sweden,4Guy's, King's, and St Thomas' Hopitals and Sarah Cannon Research Institute, Dept. ofMedical Oncology, London, United Kingdom, 5Liga Norte Riograndense Contra OCancer, Dept. of Oncology, Natal, Brazil, 6Yonsei University College of Medicine andGangnam Severance Hospital, Dept. of Urology, Seoul, South Korea, 7IstanbulUniversity-Cerrahpaşa, Dept. of Oncology, Istanbul, Turkey, 8Hospital Universitario deJerez de la Frontera, Dept. of Urology, Cadiz, Spain, 9University Hospital Schleswig-Holstein, Dept. of Urology, Lübeck, Germany, 10Kindai University Faculty of Medicine,Dept. of Urology, Osaka, Japan, 11Fudan University, Shanghai Cancer Center, Dept. ofUrology, Shanghai, China, 12Eastern Virginia Medical School, Dept. of Urology, Norfolk,United States of America, 13Janssen Research & Development, Clinical Biostats, SanDiego, United States of America, 14Janssen Global Services, Global Market Access,Raritan, United States of America, 15Janssen Research & Development, Dept. ofOncology, Beerse, Belgium, 16Janssen Research & Development, Dept. of Oncology,San Diego, United States of America, 17Janssen Research & Development, Dept. ofOncology, Los Angeles, United States of America, 18BC Cancer, Dept. of Medicine,Vancouver, Canada


31

Lunch break and poster viewing


Location Foyer


32

Pelvic nodal irradiation: Any news in the the new era of imaging?FALCON


Location Room 0.12

Chairs B. De Bari, Besancon (FR)F. Giammarile, ()F. Alongi, Verona (IT)


33

Small renal masses in patients with different comorbidity profilesPlenary Session 13


Location Auditorium

Chairs H.P.A.M. Van Poppel, Leuven (BE)K. Junker, Homburg (DE)B. Vanneste, Maastricht (NL)

14:00 - 14:10 Case presentation (including voting, 2 cases)A. Larcher, Milan (IT)

14:10 - 14:25 How to do active surveillance?A. Volpe, Novara (IT)

14:25 - 14:40 Surgery, focal: What to do when?A. Finelli, Toronto (CA)

14:40 - 14:55 Stereotactic body radiotherapy (SBRT) for kidney cancerB. Vanneste, Maastricht (NL)

14:55 - 15:10 Contrast-enhanced ultrasoundJ.M. Correas, Paris (FR)

15:10 - 15:25 Histological and molecular differentiation of small renal massesK. Junker, Homburg (DE)

15:25 - 16:00 Discussion and conclusion on cases (including voting)


34



Location Foyer


35

Combined treatment with immunotherapyPlenary Session 14


Location Auditorium

Chairs B. De Bari, Besancon (FR)A. Bex, London (GB)M. Schmidinger, Vienna (AT)

16:30 - 16:45 Immunotherapy and radiotherapyA.R. Filippi, Pavia (IT)

16:45 - 17:00 Immunotherapy and systemic treatmentT. Powles, London (GB)

17:00 - 17:15 Peri-operative immunotherapy in 2019J. Bedke, Tübingen (DE)



36

Announcement 3 best unmoderated postersPlenary Session 15

Sunday 17November08:30 - 08:45

Location Auditorium

Chairs P. Bono, Helsinki (FI)B. De Bari, Besancon (FR)R.J.A. Van Moorselaar, Amsterdam (NL)


37

Pathology in active surveillance: Update and controversiesPlenary Session 16


Location Auditorium

Chair R. Montironi, Ancona (IT)

Discussant A. Briganti, Milan (IT)

08:45 - 09:05 Pathology in active surveillanceJ. Epstein, Baltimore (US)


38

Treatment of metastatic prostate cancerDebate


Location Auditorium

Chairs P. Ost, Ghent (BE)S. Joniau, Leuven (BE)S. Gillessen Sommer, Manchester (GB)

09:15 - 10:00 Best treatment in de novo metastatic disease

09:15 - 09:25 DocetaxelS. Bracarda, Terni (IT)

09:25 - 09:35 AbirateroneP. Cornford, Liverpool (GB)

09:35 - 09:45 When to add local treatmentR. Sanchez-Salas, Paris (FR)


10:00 - 10:35 Oligometastatic recurrence - Imaging guided therapy

10:00 - 10:10 YesG. De Meerleer, Leuven (BE)

10:10 - 10:20 NoN. Mottet, Saint-Étienne (FR)



39

EU Joint Action (Innovative Partnership for Action Against Cancer IPAAC)


Location Auditorium

Chair H.P.A.M. Van Poppel, Leuven (BE)

10:35 - 10:50 EU Joint Action (Innovative Partnership for Action Against Cancer IPAAC)T. Albreht, Ljubljana (SI)


40

Take home messagesPlenary Session 19


Location Auditorium

10:50 - 11:40 Take home messages

10:50 - 11:00 Take home messageR. Montironi, Ancona (IT)

11:00 - 11:10 Take home messageC. Salembier, Brussels (BE)

11:10 - 11:20 Take home messageA. Briganti, Milan (IT)

11:20 - 11:30 Take home messageR. Oyen, Leuven (BE)

11:30 - 11:40 Take home messageA. Bamias, Athens (GR)


41

Closing remarks


Location Auditorium

Chairs L. Albiges, Villejuif (FR)P. Hoskin, Northwood (GB)H.P.A.M. Van Poppel, Leuven (BE)


42

scientific programme - emuc19 vienna 8th meeting of the ...s. shariat, vienna (at) 11:15 - 11:25...

Documents